Eevia Health Plc is experiencing a sharp spike in requests for prices and products as ripple effects from the U.S. imposed China tariffs, which now disrupt global nutraceutical supply chains.

Several major U.S.-based companies are urgently seeking alternative sources for compendial plant-based ingredients—especially low-concentrate powders—to mitigate the risk of stockouts and margin pressure caused by steep import tariffs on Chinese-origin products.

Last week, Eevia received multiple large-scale requests for quotation (RFQs) from leading U.S. buyers scrambling to secure European-origin supply. While the current U.S. tariff measures are widely viewed as temporary, uncertainty around their duration and scope has triggered a surge in near-term purchasing activity and forward-looking procurement strategies from nervous procurement managers.

“The market has suddenly shifted,” said Stein Ulve, CEO of Eevia Health. “U.S. buyers who previously relied on Chinese suppliers are now urgently looking to Europe for which tariffs are significantly lower.”

Eevia expects the situation to generate possible short-term sales opportunities, especially for low-concentrate extracts and powders, where Chinese suppliers have traditionally dominated the volume segment. The Company is currently evaluating logistics capacity and raw material availability to accommodate potential contract volumes significantly larger than normal order sizes. This unexpected development may help elevate Eevia’s strategic position as a trusted European source of sustainable nutraceutical ingredients and highlights the importance of regional supply chain resilience in the global health ingredients sector.